This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-18

Study Completion Date

2017-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a Phase I, single-center, randomized, double-blind, placebo-controlled study to evaluate the effect of aging on safety, tolerability and PK of multiple oral doses of GLPG1205 in healthy male subjects.

The study will comprise of 2 parts, a first part to investigate the effect of aging and a second part to investigate the effect of a loading dose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First-in-Human Single and Multiple Dose of GLPG1205

NCT01887106

Healthy

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

NCT04532567

Healthy

COMPLETED PHASE1

Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

NCT01208753

Healthy

COMPLETED PHASE1

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

NCT04976270

Healthy

COMPLETED PHASE1

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

NCT04856358

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Part 1, a total of 24 healthy male subjects matched for weight will be divided into 3 age groups:

* Cohort A: 8 subjects aged 65 to 74 years, inclusive
* Cohort B: 8 subjects aged ≥ 75 years (1:1 weight matched with subjects of Cohort A \[±5 kg\])
* Cohort C: 8 subjects aged between 18-50 years, inclusive (1:1 weight matched with subjects of Cohort A \[±5 kg\])

Each cohort will be randomized 3:1 to active (6 subjects) and placebo (2 subjects) treatment respectively. Weight matched subjects in Cohorts B and C will be assigned to active treatment and placebo accordingly. Cohorts A and C will be dosed with 50 mg q.d. GLPG1205 for 14 days.

In the open-label Part 2, an additional cohort of 8 subjects aged 65-74 years (Cohort D) will be included to characterize the PK profile after a loading dose followed by multiple doses of GLPG1205 q.d. for 13 days. A 250 mg loading dose will be administered on Day 1 followed by 50 mg q.d. from Day 2 to Day 14.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Elderly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLPG1205 50mg q.d.

oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo

Group Type EXPERIMENTAL

GLPG1205 50mg q.d.

Intervention Type DRUG

oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo

placebo

oral hard gelatin capsules containing placebo for q.d. administration

Group Type PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type DRUG

oral gelatin capsule containing placebo to match study arm 1 - q.d. administration

GLPG1205 250 mg loading and 50mg q.d. maintenance

open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration

Group Type EXPERIMENTAL

GLPG1205 250 loading dose and 50mg q.d. maintenance dose

Intervention Type DRUG

Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLPG1205 50mg q.d.

oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo

Intervention Type DRUG

Placebo oral capsule

oral gelatin capsule containing placebo to match study arm 1 - q.d. administration

Intervention Type DRUG

GLPG1205 250 loading dose and 50mg q.d. maintenance dose

Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male, aged over 18 years
2. Able and willing to sign the ICF.
3. Able and willing to comply with the requirements of the study.
4. Body Mass Index (BMI) between 18 and 30 kg/m² inclusive.
5. Weight between 60 and 90 kg, inclusive (Cohort A only).
6. Considered by the Investigator to be in good health.
7. Discontinuation of all medications with the exception of occasional paracetamol
8. Have a creatinine clearance (estimated by Cockroft-Gault equation) \> 80 mL/min for subjects aged up to 50 years in cohort C and \> 60 mL/min for subjects of 65 years and over in cohorts A, B and D.
9. A non-smoker and not using any nicotine-containing products .
10. Negative tests for drug screen, alcohol screen, and cotinine screen.
11. Male subjects and their female partners of child-bearing potential must agree to use a highly effective method of contraception.

Exclusion Criteria

1. Known hypersensitivity to GLPG1205 or excipients of the formulation. A history of significant allergic reaction to any drug, such as anaphylaxis requiring hospitalization.
2. Positive serology for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
3. Clinically significant illness in the 12 weeks prior to study screening.
4. Current or sequelae of gastrointestinal, liver or kidney disease or any other condition that might interfere with absorption, distribution, metabolism or excretion of drugs.
5. History of malignancy in the last 5 years.
6. Clinically significant abnormalities on ECG of rhythm or conduction
7. Clinically significant abnormalities detected on physical examination or vital signs.
8. Clinically significant abnormalities detected on laboratory safety testing
9. Significant blood loss, including blood donation of \> 450 mL, or receiving a blood transfusion or blood product in the 12 weeks prior to study screening.
10. Active drug or alcohol abuse within 2 years prior to study screening.
11. Consumption of large quantities of caffeinated coffee or tea (\> 6 cups/day), or equivalent. The consumption of alcohol, methyl-xanthine-containing beverages or foods (e.g., coffee, tea cocoa, cola and chocolate), quinine (e.g., tonic water), grapefruit or grapefruit juice, Seville oranges and poppy seeds within 48 h of study medication administration until the end of the dosing period.
12. Concurrent or recent participation in an investigational medicinal research study.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes